Thus, clinician patient discussion of risk versus benefit remains particularly important with inconsistent support and few data for adults >80 years of age. Even a small increase in geriatric-specific adverse effects with statins could offset any car- Statins may be indi- cated if, after a clinician patient discussion, the potential for benefit is thought to outweigh the risks of adverse effects, drug drug interactions, and cost. 2. A counterpoint to the rationale for statin therapy in primary prevention for adults of older ages is the compelling rationale to discontinue therapy in older adults with severe age-related man- agement complexities. Customary risks associ- ated with statins may be intensified by age (eg, CLINICAL STATEMENTS AND GUIDELINES and distinctive risks may also develop because of the broader age context (eg, multimorbidity, polypharmacy, sarcopenia, falls, frailty, and cognitive decline),S4.4.4.1-15 potentially confounding effective statin therapy. Aggregate risks increase with age and may become dis- proportionate to the extent that risks outweigh potential for meaningful benefit. Deprescribing statins becomes an important option to be Related studies are evolv- ing, particularly in the palliative care domain. One randomized trialS4.4.4.1-9 and several nonran- domized studies (albeit of relatively lower qual- ity) show feasibility and utility of deprescribing in older adults with significant management Nonetheless, these studies also show that decisions about statins are not intui- tive because many frailer or more complex patients may prefer to stay on statins precisely because they are at greatest cardiovascular risk.S4.4.4.1-16 Therefore, it is warranted that decisions about statin therapy be individualized and derived from clinician patient discussions. Moreover, given the predictable fluc- tuations of health dynamics, such shared decisions should be reconsidered regularly. 3. 